Antonio Giovanni Richetta | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Risankizumab versus Secukinumab: a real-world efficacy and cost per responder comparison in patients with psoriasis in Italy	DERMATOLOGY PRACTICAL & CONCEPTUAL	2025
Efficacy and safety of tildrakizumab in elderly patients. Real-world multicenter study (ESTER - study)	JOURNAL OF DERMATOLOGICAL TREATMENT	2024
Expression Analysis of Circulating microRNAs in Saliva and Plasma for the Identification of Clinically Relevant Biomarkers for Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders.	CANCERS	2024
Efficacy and safety of intra-class switching from Ixekizumab to Secukinumab in patients with plaque psoriasis. A multicenter retrospective study	JOURNAL OF PERSONALIZED MEDICINE	2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter study	JOURNAL OF DERMATOLOGICAL TREATMENT	2024
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study. IL PSO (Italian Landscape Psoriasis)	JOURNAL OF DERMATOLOGICAL TREATMENT	2024
The role of guselkumab in psoriatic artrithis and disease progression in patients with confirmed diagnosis of enthesitis	ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY	2024
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)	DERMATOLOGY PRACTICAL & CONCEPTUAL	2024
Therapeutic therapeutic potential of spesolimab-sbzo in the management of generalized pustular psoriasis flares in adults. evidence to date	PSORIASIS	2024
Spesolimab for the treatment of generalized pustular psoriasis. real life experience	ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY	2024
Rapid response on facial psoriasis to bimekizumab: case series	DRUGS IN CONTEXT	2024
Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2023
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)	FRONTIERS IN MEDICINE	2023
A multidisciplinary approach for patients with moderate-to-severe psoriasis: an advisable network of management	ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY	2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement	JOURNAL OF CLINICAL MEDICINE	2023
Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration	JOURNAL OF CLINICAL MEDICINE	2023
Chilblain-like lesions onset during SARS-CoV-2 infection in a COVID-19-vaccinated adolescent. Case report and review of literature	THE ITALIAN JOURNAL OF PEDIATRICS	2022
Risankizumab for the treatment of moderate-to-severe psoriasis. A multicenter, retrospective, 1 year real-life study	DERMATOLOGIC THERAPY	2022
A possible link between gut microbiome composition and cardiovascular comorbidities in psoriatic patients	JOURNAL OF PERSONALIZED MEDICINE	2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year	EXPERT OPINION ON BIOLOGICAL THERAPY	2022